

Small Molecule - November 2023

Date	Company	Cluster	About	Investment (\$Millions USD)	Financing Type	Investors / Information
11-02	Terremoto Biosciences	San Francisco	Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.	\$175.00	Series B	OrbiMed, Novo Holdings, EcoR1 Capital, Cormorant, Third Rock
11-15	NMD Pharma	Europe	NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.	\$81.40	Series B	Novo Holdings, Roche Venture Fund, Lundbeckfoden Emerge, Jeito Capital, Inker
11-07	Kynexis	Europe	Kynexis is advancing the first potential precision medicine for the treatment of cognitive impairment associated with schizophrenia (CIAS).	\$61.00	Series A	Ysios Capital, Sunstone Life Science Ventures, Forbion Capital Partners
11-07	OrsoBio	San Francisco	OrsoBio develops therapies to treat severe metabolic disorders, including type 2 diabetes, and other conditions.	\$60.00	Series A	Samsara BioCapital, Longitude Capital, Enavate Sciences, Eli Lilly
11-01	Gate Bioscience	San Francisco	Gate Bioscience specializes in a small molecule modality to treat biology's intractable diseases.	\$60.00	Series A	Versant Ventures, Google Ventures, ARCH Venture Partners, Andreessen Horowitz
11-20	Reviva Pharmaceuticals	San Francisco	a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases,	\$30.00	Post IPO Equity	
11-16	On Target Laboratories	Chicago	On Target Laboratories engages in discovering, developing, and commercializing small molecules that target specific pathological	\$30.00	Series C	Pension Fund of the Christian Church, Olympus Corp of the Americas, J&J Innovation, HIG Capital, Elevate Ventures, 3B Future Health Fund
11-02	ProJenX	New York	ProJenX is a biopharmaceutical company that develops novel small molecule therapeutics that target motor neuron degenerative pathways.	\$15.00	Series A	Medical Excellence Capital
11-23	Gachun Biotech	China	Gachun Biotech is a pharmaceutical intermediates industrialization platform that focuses on APIs, or pharmaceutical intermediates.	\$14.00	Series A	BioVenture, SI Chauan Venture
11-28	iQure Pharma	New Jersey		\$1.80	Series A	Mass Medical Angels